Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RMC 035

Next Previous
Search
Drug Profile

RMC 035

Alternative Names: A1M-001; Alfa-1-Mikroglobulin - Guard Therapeutics; Alpha-1-microglobulin - Guard Therapeutics; RMC-035; ROSgard; α1-microglobulin - Guard Therapeutics

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A1M Pharma AB
  • Developer Guard Therapeutics
  • Class Antihypertensives; Radioprotectives; Recombinant proteins; Urologics
  • Mechanism of Action Alpha 1 microglobulin replacements; Antioxidants; Free radical scavengers; Haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute kidney injury
  • No development reported Preeclampsia; Radiation injuries

Most Recent Events

  • 25 Mar 2025 RMC 035 is still in phase I development in Acute kidney injury in Sweden (IV)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Acute kidney injury in Sweden (IV)
  • 26 Aug 2024 Guard Therapeutics initiates enrolment in the phaseIIb POINTER trial for Acute kidney injury (In adults, In the elderly) in Czech Republic, Germany, Spain (IV), after August 2024 (NCT06475274)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top